

## **REMARKS**

Reconsideration of this application and reexamination of the pending claims in view of the amendments and remarks herein are respectfully requested. The listing of claims provided herein amends claims 23, 78, and 99, and adds new claims 101-103. The claim amendments are fully supported by the application as filed and do not introduce new matter. Claims 23-34 and 72-103 are pending.

Claims 23-30 and 32-34, 78-85, 87-89, and 96-103 correspond to elected Group II. Of these, claims 23-30, 96, 78-85, 98, and 99 are linking claims, which the Office concluded to be generic to Groups I-IV. Applicants present claims 31 and 86, which correspond to Group IV, and claims 72-77 and 90-95, which correspond to Group III. Applicants request that these claims directed to Groups III and IV be examined in this application upon allowance of the linking claims.

Applicants thank the Examiner for withdrawing the rejections made in the prior Office Action in view of the Amendment and Response filed April 28, 2005. In the current Office Action claims 23-30, 32-34, 78-85, 87-89, and 96-100 were rejected under 35 U.S.C. § 112, first paragraph because the Office contends the specification, while being enabling for the method of treating a *Flaviviridae* virus infection, does not reasonably enable treatment, wherein the inhibition of binding between the *Flaviviridae* virus and the effector molecule is greater than 80%.

In response, Applicants have amended the claims as suggested by the Examiner to remove the language referring to percent inhibition. Applicants submit that this Amendment obviates the stated basis for the rejection, and that the claims are fully enabled throughout their scope. In view of the amendment to the claims, withdrawal of the enablement rejection is appropriate and respectfully requested.

Applicants note that in the Advisory Action the Examiner suggested that the claim language referring to percent inhibition had been the basis for withdrawing the prior rejections over prior art. In response, Applicants submit that the claims as presently amended are patentable over the art cited previously in this application for the reasons stated in the Reply filed April 28, 2005.


Applicants respectfully submit that, in view of the amendment made herein, claims 23-30, 32-34, 78-85, 87-89 and 96-100 are allowable. Applicants renew their request that the Office rejoin claims 31, 72-77, 86, and 90-95 to the remaining claims in the application and allow them to issue together at this time.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 22, 2005

By:   
Kenneth J. Meyers  
Reg. No. 25,146